QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 d-boral-capital-maintains-buy-on-geovax-labs-maintains-9-price-target

D. Boral Capital analyst Jason Kolbert maintains Geovax Labs (NASDAQ: GOVX) with a Buy and maintains $9 price target.

 d-boral-capital-maintains-buy-on-geovax-labs-maintains-9-price-target

D. Boral Capital analyst Jason Kolbert maintains Geovax Labs (NASDAQ:GOVX) with a Buy and maintains $9 price target.

 d-boral-capital-maintains-buy-on-geovax-labs-maintains-9-price-target

D. Boral Capital analyst Jason Kolbert maintains Geovax Labs (NASDAQ:GOVX) with a Buy and maintains $9 price target.

 geovax-labs-q2-eps-035-beats-036-estimate-sales-852282k-beat-366667k-estimate

Geovax Labs (NASDAQ:GOVX) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.36) b...

 earnings-preview-for-geovax-labs
Earnings Preview For Geovax Labs
07/25/2025 19:02:12

 d-boral-capital-maintains-buy-on-geovax-labs-maintains-9-price-target

D. Boral Capital analyst Jason Kolbert maintains Geovax Labs (NASDAQ:GOVX) with a Buy and maintains $9 price target.

Core News & Articles

https://www.fox2detroit.com/news/1-person-dies-plague-northern-arizona?taid=6871388e1d7907000160979d&utm_campaign=trueanthe...

 reported-june-16-2025-geovax-labs-files-to-sell-615m-common-units-each-common-unit-consists-of-1-share-of-common-stock-and-2-common-warrants-to-purchase-1-share-of-common-stock

- SEC Filing

 geovaxs-geo-cm04s1-vaccine-shows-t-cell-responses-vs-mrna-vaccine-in-phase-2-trial-for-cll-patients-meeting-key-immunogenicity-endpoints-and-driving-continued-enrollment-at-2025-eha-congress-presentation

https://geovax.com/investors/press-releases/geovax-highlights-positive-immune-response-results-from-geo-cm04s1-in-cll-patients-...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION